150 related articles for article (PubMed ID: 36650953)
21. MN1 overexpression with varying tumor grade is a promising predictor of survival of glioma patients.
Saini M; Jha AN; Tangri R; Qudratullah M; Ali S
Hum Mol Genet; 2021 Jan; 29(21):3532-3545. PubMed ID: 33105486
[TBL] [Abstract][Full Text] [Related]
22. miR-320a functions as a suppressor for gliomas by targeting SND1 and β-catenin, and predicts the prognosis of patients.
Li H; Yu L; Liu J; Bian X; Shi C; Sun C; Zhou X; Wen Y; Hua D; Zhao S; Ren L; An T; Luo W; Wang Q; Yu S
Oncotarget; 2017 Mar; 8(12):19723-19737. PubMed ID: 28160566
[TBL] [Abstract][Full Text] [Related]
23. CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma.
Sibin MK; Bhat DI; Narasingarao KV; Lavanya Ch; Chetan GK
Tumour Biol; 2015 Sep; 36(10):7607-14. PubMed ID: 25921285
[TBL] [Abstract][Full Text] [Related]
24. The U2AF2 /circRNA ARF1/miR-342-3p/ISL2 feedback loop regulates angiogenesis in glioma stem cells.
Jiang Y; Zhou J; Zhao J; Zhang H; Li L; Li H; Chen L; Hu J; Zheng W; Jing Z
J Exp Clin Cancer Res; 2020 Sep; 39(1):182. PubMed ID: 32894165
[TBL] [Abstract][Full Text] [Related]
25. CPLX2 is a novel tumor suppressor and improves the prognosis in glioma.
Chen Y; Ning J; Shu L; Wen L; Yan B; Wang Z; Hu J; Zhou X; Tao Y; Xia X; Huang J
J Neurooncol; 2024 Mar; 167(1):63-74. PubMed ID: 38427133
[TBL] [Abstract][Full Text] [Related]
26. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
27. HIC2 promotes cell cycle transitions by upregulating CDK1 expression in glioblastoma.
Lu P; Shangguan W; Zhao Q
Asian J Surg; 2023 Oct; 46(10):4536-4538. PubMed ID: 37202257
[No Abstract] [Full Text] [Related]
28. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
Liu J; Xu K; Ma L; Wang Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
[TBL] [Abstract][Full Text] [Related]
29. EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas.
Perez-Janices N; Blanco-Luquin I; Tuñón MT; Barba-Ramos E; Ibáñez B; Zazpe-Cenoz I; Martinez-Aguillo M; Hernandez B; Martínez-Lopez E; Fernández AF; Mercado MR; Cabada T; Escors D; Megias D; Guerrero-Setas D
Oncotarget; 2015 Jan; 6(1):368-80. PubMed ID: 25621889
[TBL] [Abstract][Full Text] [Related]
30. Promoter Hypermethylation of Genes Encoding for RASSF/Hippo Pathway Members Reveals Specific Alteration Pattern in Diffuse Gliomas.
Levallet G; Creveuil C; Bekaert L; Péres E; Planchard G; Lecot-Cotigny S; Guillamo JS; Emery E; Zalcman G; Lechapt-Zalcman E
J Mol Diagn; 2019 Jul; 21(4):695-704. PubMed ID: 31055025
[TBL] [Abstract][Full Text] [Related]
31. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
[TBL] [Abstract][Full Text] [Related]
32. Integrated analysis using methylation and gene expression microarrays reveals PDE4C as a prognostic biomarker in human glioma.
Bao Z; Feng Y; Wang H; Zhang C; Sun L; Yan Z; Liu Q; Guo T; Li M; Yang X; Jiang C; Zhang Q; Jiang T
Oncol Rep; 2014 Jul; 32(1):250-60. PubMed ID: 24842301
[TBL] [Abstract][Full Text] [Related]
33. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
34. Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas.
Mellai M; Piazzi A; Caldera V; Annovazzi L; Monzeglio O; Senetta R; Cassoni P; Schiffer D
Biomed Res Int; 2013; 2013():756302. PubMed ID: 24083241
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
[TBL] [Abstract][Full Text] [Related]
36. DNA methylation-regulated YTHDF2 correlates with cell migration and immune cell infiltration in glioma.
Jiang X; Chen X; Huang X; Wang C; Wang C; Pan C; Cho WC; Nie Z; Pu J; Wang W
Aging (Albany NY); 2022 Jun; 14(19):7774-7793. PubMed ID: 35661004
[TBL] [Abstract][Full Text] [Related]
37. [Advances of glioma biomarkers].
Hao M; Liang Y; Guo R; Li X; Li Y; Wang L; Yu C; Yang Z
Sheng Wu Gong Cheng Xue Bao; 2023 Apr; 39(4):1445-1461. PubMed ID: 37154316
[TBL] [Abstract][Full Text] [Related]
38. An integrated transcriptomic and computational analysis for biomarker identification in human glioma.
Xing W; Zeng C
Tumour Biol; 2016 Jun; 37(6):7185-92. PubMed ID: 26663173
[TBL] [Abstract][Full Text] [Related]
39. Methylation Status of the RIZ1 Gene Promoter in Human Glioma Tissues and Cell Lines.
Zhang C; Meng W; Wang J; Lu Y; Hu G; Hu L; Ma J
Cell Mol Neurobiol; 2017 Aug; 37(6):1021-1027. PubMed ID: 27757741
[TBL] [Abstract][Full Text] [Related]
40. DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.
Zheng S; Houseman EA; Morrison Z; Wrensch MR; Patoka JS; Ramos C; Haas-Kogan DA; McBride S; Marsit CJ; Christensen BC; Nelson HH; Stokoe D; Wiemels JL; Chang SM; Prados MD; Tihan T; Vandenberg SR; Kelsey KT; Berger MS; Wiencke JK
Neuro Oncol; 2011 Mar; 13(3):280-9. PubMed ID: 21339190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
